Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users 
Qualcomm Stock Gains After Jensen Huang Endorsement 
BHP Port Hedland Workers Back Strike Action Amid Pay Dispute 
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
Intesa Sanpaolo Launches €30.6 Billion Bid for Monte dei Paschi to Drive Italian Banking Consolidation 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
SK Hynix Stock Rebounds as AI Memory Chip Demand Fuels Expansion Plans 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
BitGo Expands Regulated Crypto Trading Services in MENA 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu 
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges 
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
